Q2 2023 IDEXX Laboratories Inc Earnings Call

Speaker 1: Good morning and welcome to the IDEX laboratory second quarter 2023 earnings conference call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazzelski, President and Chief Executive Officer, Brian McKeon, Chief Financial Officer, and John Rabus, Vice President Investor Relations.

IDEX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.

Additional information regarding these recent uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idics.com. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles or GAP.

A reconciliation of these non- GAAP financial measures to the most directly comparable measures are provided in our earnings release, which may also be found by visiting the Investor Relations section of our website. In reviewing our second quarter, 2023 results, please note all reference to growth, organic growth and comparable growth.

refer to growth compared to the equivalent period in 2022, unless otherwise noted. To allow broad participation in the Q&A, we ask that each participant limit their questions to one with one follow-up as necessary. We appreciate you may have additional questions, so please feel free to get back into the queue, and if time permits, we'll take your additional questions.

Today's prepared remarks will be posted to the investor relations section of IDEX.com after the earnings conference call concludes. I would now like to turn the call over to Brian McKeon.

Good morning, welcome to our second quarter earnings call. Today I'll take you to our Q2 results and review our updated financial outlook for 2023.

In terms of highlights, IDEX achieved strong growth and financial performance in the second quarter aligned with our full-year performance goals. Overall revenues increased 10% organically, supported by 12% organic growth and CAG diagnostic recurring revenues, with double-digit gains in U.S. and international regions.

The execution metrics remained very strong globally, reflected in record second quarter premium instrument placements, continued solid new business gains, and sustained high growth in recurring veterinary software revenues. Operating profit results were ahead of our expectations, reflecting solid gross margin gains and operating expense leverage, both benefiting from...

nearly 12% growth in CAG diagnostic recurring revenues. We also achieved better than targeted operating margin improvement.

We've made positive refinements to our full-year operational outlook incorporating this performance, which we'll discuss later in my comments.

Let's begin with the review of our second quarter results. Second quarter organic revenue growth of 10% was driven by 11% CAG gains and 9% organic growth in our water business.

Overall organic revenue growth was constrained by modest gains in our LPD business and approximately three million dollars of headwind related to lower Opti medical revenues reflecting the wind down of our human COVID testing business. CAG diagnostic recurring revenue increased 12% organically reflecting 12% gains in the US and 10% growth.

improvement range for the first half of 2023.

Overall organic revenue growth was supported by 13% growth in veterinary software and diagnostic imaging revenues.

CAG instrument revenues were down 6% organically, reflecting comparisons to high priority levels, program pricing effects, and global mix.

IDEX CAG diagnostic recurring revenue growth remains solidly above sector growth levels.

In the U.S., we achieved a consistent strong 1,370 basis point growth premium in Q2, compared to same-store U.S. clinical visit growth levels, which declined an estimated 1.3% in the quarter.

Solid US volume growth was supported by new business gains, high customer retention levels, and continued increases in diagnostic frequency and utilization at the practice level. International CAG diagnostic recurring revenue growth improved organically to 10% in Q2, reflecting positive volume gains and benefits from higher net price realization. International results were also supported by strong IDEX execution, reflected and sustained new business gains, and record Q2 premium instrument placements, which supported a double-digit expansion of our premium instrument install base. Double-digit growth rate benefits from IDEX execution offset impacts from challenging international macro conditions.

IDEX VetLab consumer revenues increased 15% organically with double-digit gains in U.S. and international regions. Consumable gains were supported by 11% year-on-year growth in our global premium instrument install base reflecting strong gains across our catalyst premium hematology and set of U-platforms.

Catalyst placements increased 15% globally, reflecting 8% gains in the U.S. and 19% placement growth in international regions. The quality of instrument placements continues to be excellent, demonstrated by 9% global growth in new and competitive catalyst placements and solid gains in EVI metrics. Prosit-1 momentum also continues to be strong globally, reflected in a global install base of approximately 10,800 instruments.

Global rapid asset revenues expanded 12% organically in Q2, driven by strong growth in the US, reflecting solid volume gains and benefits from higher net price realization. Global lab revenues increased 9% organically, reflecting double digit gains in the US and mid-single digit growth in international.

and ongoing momentum in cloud-based software placements.

Water revenue increased 9% organically in Q2, reflecting continued solid gains in the US, Europe and Latin America, including benefits from net price improvement.

The integration of performance of our recent tech to PDS act was as she continues to progress well, expanding our capabilities in water safety testing and adding approximately 2% to reported water growth. Livestock poultry and dairy revenue increased 1% organically as strong gains in the US were offset by impacts from lower herd health screening revenues.

related to reduced China import testing. Turning to the P&L, Q2 profit results were supported by solid gross profit gains.

Gross profit increased 11% in the quarter as reported and 13% on a comparable basis. Gross margins were 60.7% up 160 basis points on a comparable basis. These gains reflect benefits from higher net price realization, lab productivity and operational initiatives, improvement in software service gross margins and business mix.

which offset inflationary cost effects. As expected, reported gross margin gains were moderated by a 60 basis point negative impact related to foreign exchange changes, including the lapping of prior year hedge gains. While foreign exchange trends have improved, we're expecting approximately 70 to 80 basis points of negative impact in year-on-year reporting.

games.

On a reported basis, operating expenses decreased 17% year-on-year, reflecting a 26% favorable growth rate impact from comparisons to prior year levels, which included $80 million in discrete R&D investment.

Adjusting for this effect, operating expense growth was modestly below revenue growth in the quarter, supporting operating margin gains.

EPS was $2.67 per share in Q2, an increase of 71% as reported.

On a comparable basis, EPFs increased 77%, including approximately 54% of growth rate benefit from lapping the $0.72 per share prior to your impact from discrete R&D investments.

Ford Exchange reduced operating profits by $8 million and EPS by 7 cents per share in the quarter, including impacts from the lapping of $6 million in prior year hedge gains.

Impacts from 2023 foreign exchange hedges were limited in the quarter.

Precastle was $173 million in the second quarter. A trailing 12 month basis, our net income to pre-castle conversion ratio was 75%.

Our balance sheet remains in a strong position. We ended the quarter with leverage ratios of 0.9 times gross and 0.7 times net of cash. Share repurchases over the last year supported a 1% reduction in diluted shares outstanding. We didn't allocate capital to share repurchases in the second quarter as we manage our balance sheet relatively more conservatively in the current interest rate environment. Turning to our 2023 P&L outlook, we're refining our full year outlook to incorporate our solid first half operating results and updated estimates for foreign exchange impacts.

Our updated full year guidance for reported revenues is $3,660,000,000 to $3,750,000, reflecting an 8.5% to 10% organic growth range.

This outlook includes a $15 million favorable adjustment for foreign exchange changes, which we now estimate will have a relatively flat full-year impact on reported revenue growth at the rate shown in our press release.

In terms of our operational growth outlook, we're maintaining our performance goals aligned with the high end of our guidance range of 10% overall organic revenue growth, supported by 11% CAD diagnostic-recurring revenue gains.

This reflects expectations for consistent strong levels of IDEX execution aligned with H1 trends.

Our outlook incorporates approximately 1% of expected H2 headwinds for CAG diagnostic recurring revenues from equivalent days effects.

Consistent with earlier guidance, our high-end outlook for CAG diagnostic recurrent revenue growth reflects expectations for 6-7% net price gains and a relative flattening of U.S. same-store clinical visit growth trends in H2.

We've raised the low end of our four-year organic revenue growth outlook by 1% to reflect our strong first half performance. We've also made positive adjustments to our outlook for operating margin performance in 2023. Our updated outlook is for reported operating margins in the range of 29.3% to 29.7% for phrases of 2%, 3%, 4%, and 4% compared to our previous next and whyApp

This includes approximately 280 basis points and combined benefits from the $16 million Q1 customer contract resolution payment and the lapping of $80 million of discrete R&D investment in the second quarter of 2022. Our operating margin outlook reflects expectations for moderated year-on-year comparable gross margin.

margins by approximately 60 basis points this year, primarily related to impacts of lapping of 26 million in 2022 hedge gains.

We estimate that foreign exchange impacts will decrease EPS by approximately 21 cents per share for the full year with approximately 2 cents per share of negative impact in the second half, including effects from hedge gain lapping.

Our updated EPS outlook is $9.64 to $9.90 per share.

This is an increase of 23 cents per share at midpoint, reflecting 17 cents in benefit from a raised operational outlook, and 6 cents in combined benefit from refined interest expense and foreign exchange estimates.

In terms of our operational outlook for Q3, we're planning for organic revenue growth at the lower end of our updated full year growth range, incorporating expected impacts from approximately 1% of equivalent day headwinds.

We expect foreign exchange to provide approximately 1.5% in reported growth rate benefit in the quarter. We're planning for operating margins in the 28.5% to 29% range, reflecting expectations for relatively consistent comparable operating margin performance.

adjusting for unfavorable foreign exchange margin impacts of approximately 50 basis points driven by hedge gain mapping.

We've provided details in our updated four-year outlook in the press release tables and earnings snapshot. That concludes our financial review. I'll now turn the call over to Jay for his comments.

Demand for medical services remains high and veterinary and see diagnostics as a core enabler to guide individualized best care. As a result, we saw strong diagnostic sector revenue growth with continued gains in diagnostics testing frequency and utilization. IDEX remains well positioned to further benefit from these trends thanks to our decades on focus on diagnostics and the software solutions that deliver key differentiated insights into the patient's health. IDEX's strong results are reflected in double digit total company organic revenue growth supported by expansion of CAGS diagnostics recurring revenues.

For the first time ever, U.S. revenues exceeded $1 billion in the first half of 2023. IDAC's execution drivers continue to fire in all cylinders as reflected in our financial results.

including growth in high quality premium instrument placements, sustained high customer retention levels, contribution from new business gains, and net price realization that remains aligned with our expectations.

IDEX commercial teams delivered yet another record quarter of global premium instrument placements.

building off high prior year levels and supporting solid EVI gains for the quarter. IDEX diagnostics and software solutions deliver key insights and productivity improvements to workflow transformation. These results demonstrate that a greater number of clinicians are partnering with IDEX with the aim to deliver higher care standards and crucial efficiency gains.

This support continues to be important given persistent clinic productivity constraints in a dynamic macro backdrop.

Today, I'll discuss how IDEX delivered continued strong performance through key strategic initiatives aimed at driving sector development. I'll start by providing an update on our global commercial execution.

It's a key component in driving increased testing utilization of both existing customers, as well as due to IDEX accounts.

Veterinarians around the world seek testing solutions that provide them with key diagnostic insights necessary to choosing and delivering the right care path in an efficient and intuitive way. IDEC's commercial teams, as trusted advisors, seek to provide the most appropriate solution given a practice's objectives. There's a deep appetite for point-of-care solutions that deliver the right performance for the solution.

ease of use, workflow integration, and economics. Therefore, it was gratifying to see a record second quarter of global premium instrument placements, with record placements in both the US and internationally.

Second quarter premium placements reflected growth across regions and platforms.

highlighting the value that clinicians across different geographies at various stages of practice maturity see in our highly innovative platforms in the integrated ecosystem.

An important dimension of this success is our menu of customer-friendly marketing programs to adopt IDEX innovations.

The result was continued solid gains in EVI and excellent contribution from new business gains including a new Key US corporate account.

Very strong ongoing placement performance and our solid relationships with accounts of all types reinforces our confidence in future flow-through of recurring revenues and our ability to address the estimated 220,000 global instrument placement opportunities.

Our commercial performance this year demonstrates that we have developed the right suite of innovative products to address this significant opportunity. PY1 is a great example of this.

It's our newest, easy-to-use premium hematology platform. Procye1 boosts efficiency gains, including Load-and-Go, reagents, and pay-per-run models, while still delivering uncompromised accuracy.

Not only does the growing hematology installed base support flow through recurring revenues, but also drives our broader in-clinic business. Sustained mid-90% attach rates with Catalysts provide a multiplier benefit that drives growth at our customer base and helps customers realize the benefits of an integrated IDEX diagnostic suite within their clinics. These multiplied effects supported the strong 15% global growth achieved in Catalysts placements in Q2.

Procyon gains globally in new and competitive accounts. Procyon also helps to advance long-term growth strategy in international regions, where most veterinarians are trained to do hematology testing when assessing a patient's baseline health.

Strong second quarter performance included, double-digit CAG diagnostics recurring revenue growth also benefited from the country-level commercial expansions we began in mid-2020.

By increasing the density of our commercial reach, IDEX sales professionals are better able to build relationships with veterinarians and communicate the benefits of diagnostics and software solution utilization, and how IDEX can support them on that journey.

By increasing the density of our commercial reach, IDEX sales professionals are better able to build relationships with veterinarians and communicate the benefits of diagnostics and software solution utilization and how IDEX can support them on that journey. The global opportunity we've identified is significant.

and these expanded commercial teams are the tip of the spear in our multimodality strategy to drive continued sector development. Benefits from these investments are highly encouraged as evidenced by strong, install-based growth supported by excellent placements and new and competitive accounts.

revenue gains from new business, and improving customer engagement levels in key international regions.

Of additional note, we have also executed a modest expansion of U.S. territories and customer-facing professionals based on highly attractive opportunities still before us in our largest geography.

We anticipate all hiring to be completed and in place by the end of this year.

In addition to high quality and quantity of instrument placements across regions in Q2, commercial execution helped drive continued adoption of IDEX innovations.

including within our rapid vector board disease screening franchise.

Our VDC teams have done a great job communicating the health benefits of a full vector board disease screen versus heartworm only testing.

We see, consequently, 40x plus making up a greater share of in-clinic vector-borne disease revenue.

This adoption is supported by our growing installed base of SnapPros, which provides an integrated solution for managing workflow and ensuring charge capture.

These focused commercial efforts, combined with relevant and easy-to-use products, highlights how we continue to build our customer base, which positions IDEX well for long-term growth.

Building on these commercial efforts, IDEX's growth will continue to benefit from advancement of our innovation strategy, a core component of which is expanding our highly accurate and relevant test menu.

We made a significant step forward in this area during the second quarter when we announced the launch of the IDEX, STAFF, and B-Test in our North American Reference Lab Network.

This novel marker leverages I-XIP to help clinicians detect kidney injury, a heart-to-diagnosed condition that comprises approximately one-third of all kidney cases seen by veterinarians.

Renal care is a critical area for diagnostics insights since the kidneys regulate blood pressure, electrolyte balance, and red blood cell production while also removing toxins.

By adding Sistatin B to our renal portfolio and by pairing it with Idexx SDMA, our customers will have access to the most comprehensive view of kidney health, helping them uncover structural injury and impaired kidney function. What's even more exciting is we will leverage our SDMA playbook to support adoption by including Sistatin B in test panels for approximately 2 million patients annually.

at no additional cost, helping clinicians realize the benefits of IDEX's world-class diagnostics and deliver a higher standard of care to their patients.

IDEX diagnostic solutions, like the innovative Sustatin B test, when used in an integrated way with our software portfolio, can contextualize an individual patient's health status.

and support the veterinarian with interpretation and drawing out the appropriate clinical insights.

Our software portfolio, which includes a full stack of solutions, many of which leverage cloud technology, touches all areas of the veterinary clinic. From enabling patient check-ins and the full diagnostics workflow, dependent on communication and charge capture, IDEC software solutions create a connected ecosystem that supports greater diagnostics utilization.

while also helping our busy customers be more efficient. A key driver of customer interest we see in our software solutions is driven by the high demand customers are seeing for medical services.

These solutions appeal to both independent and especially corporate customers who are increasingly focused on using software to standardize their workflow at scale.

Given this backdrop of high demand for pet healthcare services, busy clinics continue to appreciate the value of cloud-based products, as these intuitive and easy to administer products allow them to spend more time focusing on the patients that walk in the door, rather than on time-consuming back office tasks.

And IDEC's CloudVator products, including our EasyVet and Neo pins and WebPax imaging software, continue to be in high demand as a response to this trend. For example, second quarter cloud-based pins once again comprised over 90% of total pin space placements.

and as a result make up nearly 50% of our pin's installed base.

This is a trend we expect to continue and are well positioned to address.

In our digital imaging business, record first half instrument placement supported double-digit organic growth and demonstrate that customers are increasingly choosing IDEX to partner on this piece of their business.

and help us grow our base for future, high margin recurring revenues.

One driver of this interest is continued innovation of our Webpack software, which makes it even easier for clinicians to interpret and identify hard to detect internal abnormalities.

The result of these efforts is an excellent customer experience, which helped earn a world-class NPS rating for a diagnostic imaging business, one proof point to the solid overall experience that customers of all types have with IDEX.

This concludes our review of our second quarter results. I would like to extend my thanks to the nearly 11,000 IDEX employees who helped deliver continued strong performance aligned with our purpose of enhancing the health and well-being of pets, people, and livestock. We look forward to building on this progress.

Before we move to Q&A, I would like to remind you that we'll be hosting our annual investor day in August , beginning with the management dinner on Wednesday, August 9th, followed by presentations at our global headquarters in Westbrook, Maine on Thursday, August 10th at 8 a.m.

Thursday's event will also be live streamed and recorded via idx.com for those who cannot make it in person.

This is an exciting opportunity for the IDEX leadership team to provide updates on our strategy, execution drivers, innovation cycle, and long-term growth potential.

Participating will be members of my senior management team, including Dr. Tina Hunt, Executive Vice President, Strategy, Sector Development, and Global Operations, Dr. Mike Erickson, Senior Vice President and General Manager, Point of Care Diagnostics, Mike Lane, Executive Vice President and General Manager for Reference Laboratories and Information Technology, and Dr.

Michael Schreck, Senior Vice President and General Manager, Veterinary Software and Services and Corporate Accounts, and Brian McKean, Executive Vice President and Chief Financial Officer. We're also excited to host a live customer conversation led by Jim Polowosiek, Executive Vice President and Chief Commercial Officer, to provide a firsthand view of the role of diagnostics within the clinic.

and how IDEX is supporting our customers in adapting to the dynamic sector backdrop. The event will last approximately four hours and will conclude with a Q&A session.

And with that, we'll end the prepared section of the call and open the line for Q&A.

Thank you. If you would like to ask a question, please signal by pressing star 1 on your telephone keypad. If you are using a speaker phone, please make sure that your mute function is turned off to allow your signal to reach our equipment.

Please limit yourself to one question and one follow-up question. Again, you may press star 1 to ask a question. We'll pause for just a moment to allow everyone an opportunity to signal.

We'll take our first question from Nathan Rich with Goldman Sachs. Please go ahead.

Great. Good morning. Thanks for the questions. Two questions on volumes. I guess first in the U.S., could you maybe talk, Brian , about how clinical visits trended over the course of the quarter? I know you kind of said they had softened earlier in the quarter. Just curious how the quarter played out relative to your expectations and kind of what you're looking for.

improvement in the international CAG growth this quarter. And I think kind of despite the improvement, Reference Lab kind of remains soft. Why do you think you maybe haven't seen more improvement in Reference Lab volumes? And can you maybe talk about expectations there for the back half of the year? Thank you.

Thanks for your questions, Nate. On the first question, we saw post-January relatively similar clinical visit trends in the data. I think with hindsight, January benefited from the year-on-year COVID lapping. And overall for the first quarter, it was flat, but that benefited from that dynamic. And the Quentin

I think the clinical visit trends through Q2 were largely consistent. This was consistent with our expectation. We thought we'd see a reduction in the headwinds from the clinical visit capacity pullback that happened last year and that we were still working through some compares on that front.

time improved given the strong underlying demand that we believe is out there. So that's sort of the U.S. story. Let me give some context on international. I'm sure Jay can add to this. The strength in international came from our in-clinic business, just the very strong growth in our instrument placements, customer engagement.

support a strong consumable gains. And so I think that's directly related to our executional focus. And as you pointed out, labs were relatively consistent. We're still seeing the, have seen the macro headwinds relatively more in international markets. That's been a consistent story and.

So that moderated what were double digit growth rate benefits from the executional drivers. That enabled us to get to double digit overall growth in international markets. Yeah, and just to add to that, Nate, from a higher level standpoint, the clinic economics...

And, you know, overall health of the clinics, you know, really is healthy. I think revenue, we showed that revenue is growing nicely. So it's certainly not a demand dynamic. And as Brian said, you know, internationally we've been benefiting really over, you know, a number of quarters. –

of record placements. Procye one obviously fits well and leverages and multiplies the impact we've been able to have on total in-clinic placement. So I think very strong execution. We're now seeing the benefits of the consumables growth and that has a small ramp to it, but I think.

the, you know, the business is healthy. And we saw positive volume growth in Q2 internationally. So, you know, I think, you know, the critics are working through the type of capacity constraints and labor challenges that they've had earlier.

And we expect that to continue over time.

but we expect that to continue over time. Great. Thanks for the details.

We'll move to our next question from Chris Schott with JP Morgan. Your line is now open, please go ahead.

Hi, this is a Katerina from JP Morgan on for Chris. Thank you so much for taking our questions. So first, just some pricing. I know you probably can give too much of this as X, but directionally any initial thoughts on how you're going to approach price increases in 2024. On one hand, obviously, inflation is slow, but then you also probably...

And then the second question is, so if you think about both clinical visit growth and then utilization, any major differences between what you're seeing for your corporate clinic accounts versus your non-popular corporate but owned privately owned accounts.

So if you think about both clinical visit growth and then utilization, any major differences between what you're seeing for your corporate clinic accounts versus your non-corporate but privately owned accounts. Thank you so much.

Yeah, so good. Thanks. Thanks for your question. On the pricing front, first I just want to reinforce. We have a consistent outlook for the second half of 2023 for six to seven percent overall net price improvement related to CAG diagnostic recurring revenues.

We're not prepared to share our plans for 2024. What I would note is that we'll have as we've had in the past a very thoughtful approach that's aligned with long-term sector development in the value that we deliver through our solutions and our innovations and we'll evaluate and incorporate.

inflationary dynamics as part of that approach as we get closer to next year. Just a couple words about pricing. To Brian's point, from a philosophical standpoint, we want to make sure we continue to deliver really strong value. We think that our pricing reflects the fact that we have a lot of people who are not familiar with the pricing

We continue to do that. We see really very high retention levels in the data business. We see an increase in adoption and utilization. So from the standpoint of, you know, I think customer receptivity, we think our pricing is appropriate given the circumstances.

If you think about our latest baby release in reference labs, it's a great example of how we add value, that we're increasing the menu. Two million patients on a global basis, annual global basis are going to benefit from this. We're not increasing the price.

of those panels. I think it's just a great example of how we try to keep that value equation appropriately aligned to the

you know what our customers need. In terms of corporate versus, you know, independent practices, a couple dynamics to keep in mind. You know, largely we don't see big differences, obviously. There's differences in things like the size of the practice, corporate practices tend to be a bit larger, they're more.

They're more specialty practices owned by corporates. They're focused, I think, increasingly on growth. We've seen nice interest not just in our solutions, like in clinic premium analyzers, but also software solutions as they really try to operate the businesses in a more standardized way.

You know, they're interested in the same type of diagnostic solutions that independent practices are. We see a lot of interest in things like preventive care, for example, because it's a great way, if I think, continue to engage pet owners and clients really uncover, I think, disease that maybe otherwise subclinical or hit.

differences that I just mentioned.

We'll move to our next question from Michael Ricekin with Bank of America. The floor is yours. Great, thanks for the second question. Two quick ones for me. First, could you expand a little bit on what you saw on a quarter between wellness and clinical, and especially as it touches on preventative care in the United States, just wondering if you're starting to see, or if you are seeing any separation there, just given the price increases between last year and this year, and just being about, you know, wellness to spend consumer sensitivity if you're seeing any impact on the land from the 5 things.

And then I have a follow-up. Yeah, good morning, Mike. You know, it's not unusual to see some variability in a given quarter between wellness and, let's say, non-wellness or sick patient visits. When you take a look at Q2, on a two-year basis, there were very similar growth profiles between the two.

It's a small thing that can, you know, count for some variability, whether you're more people are traveling, whether what have you. You know, what we tend to look at is we tend to look at those diagnostic parameters or menu.

better used in wellness areas like 4Dx+, for example. And that was very strong growth. So we really haven't seen any drop off.

Okay, alright, thanks, that's helpful. And then this is a little bit of looking ahead to 3Q, but just focusing specifically on international and Europe in particular. I know in prior years you guys have seen occasionally a little bit of a headwind from weather, from extreme weather events, whether it's heat waves or hurricanes, etc., just because it would impact and transform what really affects the Project watching on digital media.

pet owner behavior or ability or willingness to visit clinics, things like that. Just thinking about the heat wave in Europe that's been going on for the last month or so, is that factoring into your guidance at all? Are you anticipating a little bit of an impact on revenue? Or have you called out a day's impact of mothering?

Yeah, my, you know, I think whether at times can have impact in the business. Our outlook that I mentioned was that for Q3 was organic revenue growth at the lower end of our full year outlook range. And that that basically aligns with consistent strong execution trends and adjustments for the days effects and just, obviously, our pricing is evolving a bit here as well. So just compared to H1. So it's targeting consistent strong execution and, you know, we'll address those types of impacts if they occur and in the business as, you know, in report on that if that turns out to be a factor.

All right, thanks. If you find that your question has been answered, you may remove yourself from the queue by pressing star two. And once again, if you would like to join the queue, you may press star one on your telephone keypad at this time. We'll take our next question from Ryan Daniels with William Blair.

Please go ahead. Yeah, good morning. Thanks for taking the questions. I just wanted to dive into the expansion of the US customer facing organization a little bit more. I know it's been a while and you've been more focused on OUS expansion. So can you talk a little bit about, you know, strategically what drove that? Is it just new clinic openings? Are you seeing more opportunities to visit?

been over three years since we did the last expansion. We're very optimistic about the long-term growth prospects of the U.S. It's our largest market. It's something that we really evaluate on an ongoing basis. We want to make sure that we have the right account coverage and we're able to support.

product and innovation priorities over time. So we felt that it made sense. It really just comes down to that.

Okay, great. And then it's been a while since you've talked about a new big corporate win. And I'm curious if you could talk about maybe the competitive environment more broadly post some M&A activity in your space. Are you seeing that open up any opportunities or just normal course of business or more innovation? We'll see. I think the idea that it's global individuals areworld countries.

Yeah, I mean, I think it's a really normal course of business. We do very well with corporates. We occasionally talk about it. But from a corporate account standpoint, I think they see, increasingly see, the integrated benefits of multimodality solution and software. They're focused on workflow and they're focused on...

productivity, given the capacity constraints and the need to really operate these models. And I think from a solutions standpoint, they appreciate what we're able to bring. We have a footprint that's obviously very broad and deep and can work, can partner with them wherever they are. So I think it's a very natural fit from that standpoint.

Great, thank you so much. We'll move to our next question from John Block with people. Please go ahead. Thanks guys and good morning. I'll bring up my questions. Brian , it seems like the visits are expected to get a bit better in the second half of 23. I think if I had it right, you mentioned flatish, give or take your...

23 visits from those first half levels. We did some work around labor constraints that might be easing a bit, but we'd love your thoughts on the improvement in 2H23. And then do we think about that trend line arguably continuing into 2024? It'll ask my follow-up.

Yeah, thanks John for your question. I think the, a part of it is working through this effect we saw in 2022 where there was a pullback in capacity. And so I think the, that pullback was largely happening in the first half of 2022 and so …

We knew we'd still be working through some of that, and I think that there'll be some relative improvement, which I think you were pointing out. And I think overall, we anticipate that we continue to look at the growth in demand that we see in terms of the expansion of the pet population and...

increased interest in pet healthcare, that being affirmed in a lot of the qualitative work that we do, believe that there's underserved demand and believe that that will be a positive tailwind over the long term, continue to feel that's very much part of the.

the growth build that we have for the long term. And we're working through some dynamics here to help clinics adapt to that and improve their productivity and I think we can be helpful. So I think our long term optimism is intact, that should be a positive driver over time and we're.

you know, we've made some positive transitions here during their first part of this year. I'd also highlight, you know, sometimes we spend a lot of time on the US trends that the, you know, internationally we've seen relatively more kind of same store headwind effect that we've been able to offset with our benefits from our business expansion and engagement and

and invasions that we're bringing in. And I think internationally, we see the same kind of a story, that over time that there's very strong demand for pet health care and probably relatively greater macro impacts in the near term. But we think that over time that will improve as well.

Got it. That was a very helpful thing for that. And maybe just a pivot to innovation. You know, when I look back to set of you, I believe there was a stagger launch with the US leading in the international following any color and how we think of those pending new systems. Will we see?

sort of the same approach play out, you know, the staggered call it. And then, I don't know if you've talked about this before, but will the manufacturing be handled by yourself or your partners on those new systems? And just, sorry, a quick clarifying question. Brian , I think price in the quarter, if I got you right, was closer to 9% for 2Q.

but his full year 2023 price still expected to be between 7 to 8. Thanks guys.

I'll add Jay dive into the platforms on your flatter question. Yes, that's correct. That's what we said. Yeah, so from a platform standpoint, I'm obviously not going to talk about it until we talk about it and get closer to the launch. What I will say, John , from a premium instrument placement and how we think about the opportunity.

We typically do start with the US market, but there's nothing that says we have to do that. The key is really to build an installed base and get that consumable revenue stream moving. That takes time. I think the set of you was one example.

And, you know, we launched it seven plus years ago and we built the install base and we have a nice profile. So we really focus on being able to really drive sector development and adoption and solve those clinical problems and everything else takes care of itself from there.

Thanks, guys. Thank you. Our next question comes from David Westenberg with Piper Sandler. Please go ahead. Hi. Thank you for taking the questions and congrats on continued strong execution here. So just a quick question again on that theme of pricing.

really what we're seeing. Are you seeing pressure from your customers to raise prices themselves? And do you think that's gonna continue for say maybe the next six months or so? And if you see any kind of potential to maybe ease in volume as their prices go up or is it kid equilibrium is because.

That's quite a different question today. Let me just start with the price increase. Obviously, clinics control that if you go back the last five or six quarters. A lot of clinics took multiple price increases on an annual basis. They typically, if you go pre-pandemic or pre-inflationary times, they would increase their prices one time per year, I think a number of clinics on average increase at least two, in some cases.

And that was really just to reflect the higher costs of labor and retaining staff and in some cases they needed to add to staff. And so from an employment level standpoint, you know, we think clinics are catching up or caught up. They've hired people. That's not to say they're all working.

you know, 40 hour weeks. And so, you know, in terms of pricing going forward, I think that's really just a reflection of what happens, you know, in the economy. You know, at this point it appears that inflation, you know, has moderated, you know, somewhat, but we'll have to see how that plays out and I think they'll make decisions.

from in 2022 as the dollar was strengthening, we hedge out, we tend to hedge in advance of the year to help us with our planning. And we had in the second half of last year, eight recognized the benefit from $18 million in hedge gains.

So what's happened with the foreign exchange dynamics is they've actually moved into a positive zone, you know, so we have some benefit on revenue, but we're going to have some reported year-on-year foreign exchange headwinds, we estimated 70 AAD basis points in age two, that relate to

just lapping those hedge gains that will roll off eventually. So just trying to highlight that as a factor. We try to each quarter note what those gains or losses are so you have that and that's in our disclosures as well. So but just wanted to highlight that as you're to understand kind of the outlook.

Thank you for taking my long questions. Our last question comes from Balaji Prasad with Barclays. Please go ahead.

Hi, this is Michaela Ancivilizzi. Thanks for taking our questions. Can you talk about anything particular you saw in the quarter that drove the two-year stacked growth to celebration in category 3? Thank you so much. So I have a question. Anything that?

Was there anything that drove the two-year stack, CAG diagnostics, recurring revenue growth?